403 related articles for article (PubMed ID: 27583312)
21. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study).
Nakamura M; Nishikawa M; Komuro I; Kitajima I; Uetsuka Y; Yamagami T; Minamiguchi H; Yoshimatsu R; Tanabe K; Matsuoka N; Kanmuri K; Ogawa H
Circ J; 2015; 79(6):1230-6. PubMed ID: 25912695
[TBL] [Abstract][Full Text] [Related]
22. Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.
Guntupalli SR; Brennecke A; Behbakht K; Tayebnejad A; Breed CA; Babayan LM; Cheng G; Ramzan AA; Wheeler LJ; Corr BR; Lefkowits C; Sheeder J; Matsuo K; Flink D
JAMA Netw Open; 2020 Jun; 3(6):e207410. PubMed ID: 32589230
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
Dawwas GK; Smith SM; Dietrich E; Lo-Ciganic WH; Park H
Am J Health Syst Pharm; 2020 Jan; 77(3):188-195. PubMed ID: 31974557
[TBL] [Abstract][Full Text] [Related]
24. Safety Outcomes of Apixaban Compared With Warfarin in Patients With End-Stage Renal Disease.
Sarratt SC; Nesbit R; Moye R
Ann Pharmacother; 2017 Jun; 51(6):445-450. PubMed ID: 28478715
[TBL] [Abstract][Full Text] [Related]
25. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
26. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Nieto JA; Espada NG; Merino RG; González TC
Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
[TBL] [Abstract][Full Text] [Related]
27. Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population.
Guo JD; Hlavacek P; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Thromb Res; 2021 Feb; 198():163-170. PubMed ID: 33348190
[TBL] [Abstract][Full Text] [Related]
28. Anticoagulation prescribing patterns in patients with cancer.
Xiang E; Ahuja T; Raco V; Cirrone F; Green D; Papadopoulos J
J Thromb Thrombolysis; 2018 Jan; 45(1):89-98. PubMed ID: 29052104
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
Lassen MR; Davidson BL; Gallus A; Pineo G; Ansell J; Deitchman D
J Thromb Haemost; 2007 Dec; 5(12):2368-75. PubMed ID: 17868430
[TBL] [Abstract][Full Text] [Related]
30. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Hornick P;
Lancet; 2010 Mar; 375(9717):807-15. PubMed ID: 20206776
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment.
Stanton BE; Barasch NS; Tellor KB
Pharmacotherapy; 2017 Apr; 37(4):412-419. PubMed ID: 28117916
[TBL] [Abstract][Full Text] [Related]
32. Characterizing the Safety Profile of Apixaban Versus Warfarin in Moderate to Severe Chronic Kidney Disease at a Veterans Affairs Hospital.
Herndon K; Guidry TJ; Wassell K; Elliott W
Ann Pharmacother; 2020 Jun; 54(6):554-560. PubMed ID: 31872779
[No Abstract] [Full Text] [Related]
33. Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Portman RJ
N Engl J Med; 2009 Aug; 361(6):594-604. PubMed ID: 19657123
[TBL] [Abstract][Full Text] [Related]
34. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T
Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024
[TBL] [Abstract][Full Text] [Related]
36. Comparison of inpatient admission rates of patients treated with apixaban vs. warfarin for venous thromboembolism in the emergency department.
Deitelzweig S; Hlavacek P; Mardekian J; Rosenblatt L; Russ C; Tuell K; Lingohr-Smith M; Lin J; Guo JD
Hosp Pract (1995); 2020 Feb; 48(1):41-48. PubMed ID: 31976776
[No Abstract] [Full Text] [Related]
37. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
38. Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.
King DA; Pow RE; Dickison DM; Vale PR
Intern Med J; 2016 Sep; 46(9):1030-7. PubMed ID: 27246450
[TBL] [Abstract][Full Text] [Related]
39. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
Brekelmans MP; Bleker SM; Bauersachs R; Boda Z; Büller HR; Choi Y; Gallus A; Grosso MA; Middeldorp S; Oh D; Raskob G; Schwocho L; Cohen AT
Thromb Haemost; 2016 Jul; 116(1):155-61. PubMed ID: 27010092
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X
Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]